Pathology (PSR)
病理学(PSR)
基本信息
- 批准号:10311231
- 负责人:
- 金额:$ 10.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-08-04 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AccreditationAcute Myelocytic LeukemiaAdultBiological AssayBiological MarkersBudgetsCLIA certifiedCancer Center Support GrantCell TherapyChildhoodClinicalClinical DataClinical TrialsComputer softwareDataDatabasesEnvironmentFundingGastrointestinal Stromal TumorsGene MutationGenesGenomicsGliomaHistologyHumanImmunofluorescence ImmunologicIonsLaboratoriesMalignant NeoplasmsMedicineMetastatic MelanomaMutationMyelogenousNon-Small-Cell Lung CarcinomaNorris Cotton Cancer CenterOncogenesPathologyPatientsPhysiciansPublicationsResearchResearch PersonnelResource SharingRoleSamplingScientistServicesSolid NeoplasmSomatic MutationSpecimenSystemTechnologyTestingTranslational Researchbiobankbiomarker developmentbiomarker discoverycell free DNAdata miningdata warehousedesignfusion genegene panelgene therapygenomic datamembermetastatic colorectalmultidisciplinarynext generation sequencingpersonalized medicineprogramsresearch clinical testingsarcomatargeted treatmenttriple-negative invasive breast carcinomatumor
项目摘要
Project Summary/Abstract: Pathology
The Pathology Shared Resource (PSR), a designated Norris Cotton Cancer Center (NCCC) Shared Resource
facility, was created to provide NCCC investigators access to the latest technologies for biobanking and
biomarker testing in a CLIA-licensed, CAP-accredited laboratory environment. The CLIA/CAP standards are
essential to the support of clinical trials, biomarker discovery studies, and the transition of research findings to
clinical testing. The PSR is housed under the umbrella of the laboratory for Clinical Genomics and Advanced
Technology (CGAT) in the Department of Pathology and Laboratory Medicine. Major PSR services span
histology, genomics, cell therapy, and the institutional biorepository. Since the last review, the Shared
Resource has moved into 10,000 sf of new space in the Williamson Translational Research Building. The lab
acquired an Ion Torrent Chef-55 system to support its role as a central reference lab for both the adult and
pediatric NCI MATCH trials. Next generation sequencing services now include a 50-gene cancer hotspot
panel, a 50-gene solid tumor fusion gene panel, and a 54-gene myeloid panel, resulting in a somatic mutation
database of more than 4,000 patient tumors now available for investigator-initiated data mining. For the Adult
MATCH trial, the laboratory has sequenced 280 samples, and for the Pediatric MATCH trial we have
sequenced 292 samples to date. The PSR has established a somatic mutation database for routinely tested
human cancers that includes glioma, triple negative breast cancer, non-small cell lung cancer, metastatic
colorectal cancer, metastatic melanoma, gastrointestinal stromal tumor, sarcoma, and acute myeloid leukemia.
These data have resulted in numerous multidisciplinary publications evaluating mutation profiles within and
across tumor types. Institutional biorepository samples are annotated in eSample, a module of Velos which is
supported by the NCCC and has connectivity with the clinical trial program eResearch, also a module in Velos.
I2B2 connectivity will facilitate the design of targeted therapies in personalized medicine. Since 2014, PSR has
provided over 20,000 units of service to 60 current NCCC Members across all four Programs. Funded NCCC
Members since 2015 have represented 77% (49) of Total Users, and we are requesting only 38% of the Total
PSR budget from CCSG support. Additional multiplex IHC assays, immunofluorescence and expanded gene
mutation panels are being developed to further support more advanced investigator-driven applications. In
addition, the laboratory continues to develop cell-free DNA assays and expand the institutional biorepository
with implementation of the BC Platform specimen/data warehousing software that will allow investigators portal
access to Independent Bill Review (IBR) specimens curated with clinical and genomic data.
项目摘要/摘要:病理学
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory James Tsongalis其他文献
Gregory James Tsongalis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory James Tsongalis', 18)}}的其他基金
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 10.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 10.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 10.88万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 10.88万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 10.88万 - 项目类别: